LB Pharmaceuticals Q4 EPS $(0.45) Beats $(0.63) Estimate.

LB Pharmaceuticals (NASDAQ:LBRX) reported Q4 earnings with a loss of $(0.45) per share, surpassing the analyst estimate of $(0.63) by 28.57%. This marks a significant improvement compared to the same period last year, where the company reported losses of $(14.12) per share, reflecting a 96.81% decrease in losses.